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Abstract 
 
Introduction: Statins are recommended first-line treatment for hyperlipidaemia, with published studies 
suggesting limited differences between them. However, there are reports of under-dosing. South Africa 
has introduced measures to enhance generic utilisation. Part one documents prescribed doses of statins 
in 2011. Part two determines the extent of generics versus originator and patented statins in 2011 and 
their costs. Results: Underdosing of simvastatin in 2011 with average prescribed dose of 23.7mg; 
however, not for atorvastatin (20.91mg) or rosuvastatin (15.02mg). High utilisation of generics versus 
originators at 93% to 99% for atorvastatin and simvastatin, with limited utilisation of single sourced statins 
(22% of total statins - defined daily dose basis), mirroring Netherlands, Sweden and UK. Generics priced 
33% to 51% below originator prices. Discussion: Opportunity to increase simvastatin dosing through 
education, prescribing targets and incentives. Opportunity to lower generic prices with generic simvastatin 
96% to 98% below patented prices in some European countries.   
 
Introduction 
 
Statins (HMG CoA reductase inhibitors) are recommended as first-line treatment in patients with 
hypercholesterolaemia and are used extensively to reduce morbidity and mortality, especially in high risk 
patients and for secondary prevention (1-12). This follows the publication of outcome studies such as the 
4S study and the heart protection study, both with simvastatin, as well as corresponding studies with 
other statins (5, 8, 9). Overall, statins lower blood cholesterol levels and reduce the relative risk of 
coronary events by approximately 30% in both primary and secondary prevention (4, 13).   
 
Studies have suggested that there is little difference in effectiveness between the various statins at 
appropriate doses (14-18). This has resulted in initiatives among health authorities across countries to 
encourage the prescribing of low cost generic statins compared with single-sourced (patented) statins to 
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conserve resources without compromising care. Measures that have been instigated include educating 
physicians through academic detailing, formularies and guidelines, prescribing targets, therapeutic 
switching programmes, restricting the prescribing of patented statins to patients failing to reach target lipid 
levels with generic statins as well as delisting single-sourced statins from the current reimbursement list 
once generics became available. The latter happened in Germany as there was no demonstrable 
difference in outcomes between patented and multiple sourced statins (1, 12, 16-26).  
 
Published  studies such as the Heart Protection study have led respected guideline groups such as the 
Scottish Intercollegiate Guidelines Network (SIGN) group in Scotland to just recommend 40mg 
simvastatin for the prevention of cardiovascular disease as well as for primary prevention in patients with 
Type 1 diabetes. In addition, recommend 40mg simvastatin or 10mg atorvastatin for the prevention of 
cardiovascular disease in patients with Type 2 diabetes, irrespective of their starting lipid levels (9, 11, 12, 
20). However, prescribed doses of statins have varied considerably across countries. For instance, a 
recent analysis of a cohort of patients aged 18 years or older in Finland showed that patients prescribed 
statins for the first time were typically initiated with either 10mg or 20mg simvastatin (94% of the cohort). 
In addition, a considerable proportion of patients initiated on statin therapy with less potent doses 
remained at the initial dose after 1 year (27). This suggested potential underdosing was common, even 
among patients with high cardiovascular risk (27). Similar findings were seen in Ireland, the Netherlands 
and the Stockholm Healthcare Region, Sweden, with the average dose of simvastatin for secondary 
prevention in patients in Ireland at 22mg (22, 28). In the Netherlands, many patients were prescribed 
starting doses at just over 15mg (mean dose 1.02 +/- 0.39 defined daily doses) (29). In the Stockholm 
healthcare region, the average prescribed dose of simvastatin was 20.4mg, with an appreciable 
proportion of patients prescribed only 10mg simvastatin (20, 22). There was also variable dosing of 
statins among the different regions in Norway. The authors found that patients in the high statin 
consumption regions in Norway had the highest prescribed daily dose (PDD) for simvastatin across all 
patients at 25.9 mg; similarly for atorvastatin at 21.9 mg. In addition, more users in the high consumption 
statin regions received statin tablets in the upper range of available strengths compared with the low 
consuming regions (30). There was also variable prescribed doses of statins in South Africa in the study 
of Raal et al (2) (Table 1), with low doses of simvastatin prescribed compared with recommended doses 
of 40mg in high risk patient groups such as those with diabetes (12, 31). However, higher doses of 
atorvastatin were prescribed (Table 1) (2). 
 
Table 1 ± Prescribed daily doses of simvastatin and atorvastatin in the study of Raal et al (2) 
 
Statin Number of patients %
Simvastatin
10mg 11 21.6
20mg 11 21.6
40mg 22 43.1
80mg 3 5.9
Atorvastatin
10mg 13 7.7
20mg 53 31.4
40mg 79 46.7
80mg 16 9.5
other 8 4.7  
 
In a more recent study conducted in South Africa by Raal and colleagues, 48% of patients did not reach 
target low-density lipoprotein cholesterol (LDL-C) levels (32). Any underdosing needs to be addressed as 
this significantly increases SDWLHQWV¶ULVNRIdeveloping or progressing their cardiovascular disease with 
reduced cardioprotection (33). In addition, it puts them at risk for heart attack or stroke (4). Consequently, 
dyslipidaemia appears to remain a major cardiovascular risk factor in the South African population.  
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The next key issue for health authorities is to enhance the prescribing of low cost generics once they are 
available versus originators and single-sourced (patented) products in a class if all products in the class 
are seen as therapeutically similar at appropriate doses. This applies to the statins (14, 24). South Africa 
implemented mandatory generic substitution in May 2003, making it a legal requirement according to the 
Medicines and Related Substances Act (Act 101 of 1965) (34) to inform patients of the availability of 
alternative generic medicines to allow them to make informed choices. Alongside this, many medical aid 
schemes in South Africa will only reimburse the cost of the generic product with medicine selection for 
high volume low cost medicines generally based on price (35), and a co-payment is required from 
patients if they want to be prescribed and dispensed the more expensive originator product. 
 
This paper will be divided into two parts. The first part will summarise published studies , regarding 
prescribed doses of statins including more recent findings in  South Africa (36). This will be compared 
with countries that have increased doses of statins prescribed to provide future direction. The second 
part, which is an original study, will examine the extent of prescribing of generic versus originator statins 
as well as patented statins in the same year (2011) to determine whether further measures are needed in 
South Africa to enhance prescribing efficiency among patients enrolled into medical aid schemes. The 
authors would expect to see considerable utilisation of generic versus originator and single-sourced 
statins in South Africa. As a result, similar to  the recent findings with the proton pump inhibitors in South 
Africa (37). This will also be similar to  statin utilisation patterns in the Netherlands, Sweden and the UK 
after the introduction of  generic simvastatin in these three countries with their extensive demand-side 
measures (1, 20, 21). The authors will also examine the utilisation of ezetimibe given current concerns 
and ongoing studies evaluating whether there is increased reduction in cardiovascular events with 
ezetimibide versus 40mg simvastatin (18, 38-42). 
 
Part 1 - Published studies of statin dosing 
 
The aim of the South African study published in 2014 was to analyse the prescribed doses of statins 
following an increase in the defined daily doses of statins (DDDs ± the average maintenance dose per 
day for a medicine used for its main indication in adults (43, 44)), where the DDDs of five of the six statins 
were increased to reflect current dosing recommendations in January 2009 (36). This included 
atorvastatin, increased from 10mg to 20mg, and simvastatin, increased from 15mg to 30mg (36, 43). 
 
This published study involved a retrospective, cross-sectional pharmacoepidemiological study on claims 
data from a medical insurance (medical aid) administrator in 2011 (36).  The study covered patients 
whose medical records are administered by one of the medical aid scheme administrators (private 
insurance) in South Africa, with the database containing 2,298,312 records for medicine, medical devices 
and procedures.  Each medication record contained information on the age and gender of the patient, 
with a unique number to identify each patient, the date of the prescription, detailed information on the 
dispensed drug, e.g. name, package size, formulation, strength and quantity, as well as the amount 
claimed and paid. A total of 4 805 patients (57% males) were prescribed 38 373 hypolipidaemic agents 
(Table 2). Statins constituted 94% of all prescriptions for lipid lowering drugs, with simvastatin contributing 
67% of all statin prescriptions (Table 2). The findings can be considered representational of the South 
African private health care system with the database including patients from the different provinces. 
 
4 
 
Table 2 ± Prescribing frequency (based on the total number of prescriptions) of hyperlipidaemic drugs in 
2011 in South Africa (adapted from (36)) 
 
HYPOLIPIDAEMIC CLASSES Number of 
patients 
% 
Fibrates 1 387 3.6 
HMG CoA Reductase Inhibitors (statins). The 
breakdown of their prescribing was: 
x Atorvastatin ± 16.2% 
x Fluvastatin ± 0.9% 
x Lovastatin ± 1.0% 
x Pravastatin ± 0.8% 
x Rosuvastatin ± 12.4% 
x Simvastatin ± 66.7% 36 014 93.9 
*Cholesterol Absorption Inhibitors (Ezetimibe 
alone or in combination with simvastatin) 818 2.1 
Hypolipidaemic Agents (Others ± including 
cholestyramine) 342 0.4 
TOTAL 38 373 100 
*NB Some of these patients are included in the simvastatin group as well 
 
The average prescribed daily dose (PDD) of the statins was generally lower or in agreement with the 
revised respective DDD (Table 3). The exception was rosuvastatin whose average PDD was higher 
(Table 3).  The average PDD of three most prescribed statins (Table 2) was simvastatin 23.7mg, 
atorvastatin 20.9mg, and rosuvastatin 15.0mg (Table 3). PDDs are defined as the average dose 
prescribed according to a representative sample of prescriptions, i.e. the average amount of a medicine 
actually prescribed in routine clinical practice.  
 
Table 3 ± DDDs and PDDs in mgs for the various statins in South Africa in 2011 (adapted from (36)) 
 
Atorvastatin Fluvastatin Lovastatin Pravastatin Rosuvastatin Simvastatin
DDD (mg) 20 60 45 30 10 30
Average PDD (mg) 20.91 57.29 26.31 25.35 15.02 23.7
PDD (Males) (mg) 21.6 55.59 28.33 25.74 15.97 23.8
PDD (Females) (mg) 19.84 55.59 28.33 25.74 15.97 23.8  
 
Table 3 shows that the PDDs of statins have increased in South Africa in recent years compared with a 
previous study conducted in the early to mid 1990s (45). In this study, the average PDD for simvastatin 
was 12.6 mg and for pravastatin was 12.5 mg. However, seemingly there has been limited change from 
the findings of Raal and colleagues in 2007 described in Table 1.  
 
The limited utilisation of fibrates (Table 2) is welcomed with bezafibrate (accounting for 91% of total 
fibrates) showing no significant difference in five-year coronary event rates compared with placebo (9.4% 
reduction, p  0.26) when used for secondary prevention (46).  
 
Potential ways forward in South Africa to increase the prescribing of higher strength statins could include 
additional education initiatives including prescribing guidance encouraging the prescribing of higher doses 
of simvastatin as there appears to be limited problems with PDDs of atorvastatin or rosuvastatin, which 
are the next two most prescribed statins (Table 2). This advice builds on the findings in Scotland following 
the publication of the Heart Protection Study (9, 11, 12, 20). In addition, potential prescribing indicators for 
statins especially in secondary prevention (47). These initiatives could be combined with financial 
incentives for physicians to encourage them to treat patients to agreed target cholesterol levels. This is 
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the situation in the United Kingdom with the introduction of the Quality and Outcomes Framework (QoF), 
which includes patients with diabetes, hypertension and coronary vascular disease (1, 20, 23, 48). These 
combined factors enhanced the prescribing of higher strength simvastatin in Scotland (Figure 1), with 
similar findings for atorvastatin (20). These were similar to the findings in one English primary care group 
(23). 
 
Figure 1 ± Number of different strength simvastatin tablets dispensed in Scotland 2000 ± 2010 
(Reproduced with kind permission of the journal) (20) 
 
 
 
 
Part 2 - Original research study 
 
The same datasets used in the 2014 publication (36) were used to determine the extent of prescribing of 
the different statins, including both generic and originator statins, broken down by DDDs (43). 
Reimbursed expenditure/ DDD was also calculated in South African Rand (ZAR) to calculate price 
reductions between the originator and the generics and to compare with findings with price reductions 
seen in the Netherlands, Sweden and the UK. These three countries were chosen as aggressive pricing 
policies in these three countries have resulted in the prices of generic statins as low as 2% to 4% of the 
originator  price prior to patent loss, i.e. prior to multiple sources becoming available  (20-22). 
 
Only data from chronic prescriptions, i.e. 28 or 30 days medicine supply per prescription, were used in the 
analysis to give an accurate picture of their long term use in the prevention of cardiac events in patients 
with cardiovascular disease. 
 
Simvastatin dominated statin utilisation when prescriptions were converted to DDDs at 56% of total 
statins followed by 21% for atorvastatin and 20% for rosuvastatin. This is similar to the situation when 
prescription data was analysed (Table 2). Typically, statins were prescribed as the generic once they 
became available (Table 4), greatest for simvastatin at 99% of total simvastatin, with single sourced 
(patented) statins (rosuvastatin, pravastatin and lovastatin) accounting for 22% of total statin utilisation in 
2011 (DDD basis).  
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Table 4 ± Prescribing of generic  versus originator statins (DDD basis) in 2011 in South Africa 
 
Statin % generic
Atorvastatin (4 branded generics) 93
Pravastatin (3 branded generics) 82
Simvastatin (15 branded generics) 99  
 
There was also variability in expenditure/ DDD for originator and generic statins (Table 5). Price 
reductions for the generics varied between 33% and 51%, i.e. 67% to 49% of the originator prices.  
 
Table 5 ± Reimbursed expenditure/ DDD (ZAR) of the various statins in South Africa in 2011 
 
 
STATIN TYPE Expenditure/DDD (ZAR) % Reduction
Atorvastatin ALL 3.92
ORIGINATOR 6.20
GENERICS 3.74 40
Fluvastatin ALL 8.51 No generics
Lovastatin ALL 8.00 No generics
Pravastatin ALL 9.09
ORIGINATOR 12.46
GENERICS 8.34 33
Rosuvastatin ALL 5.68 No generics
Simvastatin ALL 2.09
ORIGINATOR 4.23
GENERICS 2.06 51  
 
The appreciable prescribing of generic simvastatin at 99% of total simvastatin in 2011 (Table 4) is similar 
to the findings with generic lansoprazole and omeprazole at 98% to 99% of total prescriptions for these 
two PPIs in South Africa in 2010 (37). In addition, the low utilisation of singled sourced statins at 22% of 
total statins is similar to the low utilisation of esomeprazole (principal single sourced PPI) at 20% of total 
PPIs in 2010 (37) The high utilisation of generic simvastatin is  similar to the situation in the England 
(97% of total simvastatin in 2007), Netherlands (98% of total simvastatin in 2010), Scotland (98% in 2010) 
and Sweden (98% of total simvastatin in 2007) (1, 20, 21). In the Netherlands, Sweden and the UK, there 
was also a reduction in the utilisation of patented (single-sourced) statins following the availability of 
generic simvastatin as a result of the instigation of multiple demand-side measures (1, 20, 21).  This 
compares with France and Ireland where there was an increase in the utilisation of patented statins 
following generic simvastatin with their limited demand-side measures to combat the influence of the 
pharmaceutical companies (1). As a result, reimbursed expenditure on the statins in Ireland in 2007 with 
its limited demand-side measures and high prices for generics was over ten times that seen in Sweden 
when adjusted for population size. However, the population in Ireland had higher morbidity (1). This 
suggests that the reforms in South Africa to encourage the prescribing of low cost generics when 
available appear to be working well. This is further seen with the limited utilisation of ezetimibe alone or in 
combination at 2.1% of total lipid lowering drugs in 2011 (Table 2). This is welcomed given the current 
controversies surrounding the value of ezetimibe in clinical practice. This low rate was similar to the low 
utilisation of ezetimibe (alone or in combination) at 3% of total ezetimibe and statins (DDD basis) in 
England and Sweden in 2007 (1). This compared with France at 8% in 2007 with less demand-side 
measures to counter-act the marketing activities of the pharmaceutical company (1). 
 
The appreciable prescribing of generic statins suggests there appears to be no problems with branded 
generic statins in South Africa. This mirrors the situation in Europe (1, 20-22, 49). The authors 
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acknowledge though that this cannot be said with complete confidence as no specific studies were 
undertaken comparing the outcomes of the different branded generic statins with their respective 
originators in South Africa. However, the findings suggest there should be no problems in routine clinical 
practice. 
 
The domination of simvastatin in both prescriptions (Table 2) and DDDs compared with the findings of 
Raal and colleagues in 2007 (Table 1) may well be due to the earlier launch of branded generic 
simvastatin at lower costs than patented atorvastatin, with the lower expenditure/ DDD for generic 
simvastatin still persisting (Table 5). Again though the authors cannot say this with certainty as this was 
not specifically researched. 
 
However, there does appear to be relatively high prices for generic statins in South Africa (Table 5). As 
mentioned, this compares with the low prices for generic simvastatin in the Netherlands, Scotland and 
Sweden at between 2% to 4% of the prices or the originator before patent loss, i.e. 96% to 98% price 
reduction, despite strict bioequivalence criteria (20-22). Further research has shown that population size 
does not appear to be a barrier to countries obtaining low prices for generics as seen in Lithuania and the 
Republic of Srpska (50, 51). Potential ways forward for South Africa to achieve lower prices for generics 
could include either instigating a prescriptive pricing policy for generics as seen in Austria (60% below 
pre-patent loss prices by the time the third generic is launched), France (55% below initially) or Norway 
(maximum of 85% below pre-patent loss prices for high volume generics); alternatively instigating 
aggressive market forces (52-55). Aggressive market forces could include increased transparency in the 
pricing of generics as seen in the UK with high International non-proprietary name (INN) prescribing rates 
coupled with regular requests for companies to provide data on the cost of producing generics as well as 
any rebates or discounts given to wholesalers or pharmacists to preferentially dispense a particular 
generic (20, 23). Alternatively, instigating tendering systems as seen in the Netherlands and Sweden (21, 
55). In Sweden there are now monthly auctions whereby the manufacturer that wins the bid for their 
particular generic, typically the lowest bid,  is guaranteed an appreciable percentage of prescriptions the 
following month (55, 56). These are considerations for the future. 
 
There can also potentially be patient confusion if different branded generics each with different names are 
dispensed each time. This happens in Sweden (22, 56) if patients do not receive adequate information 
about their medicines (22, 57). As a result, potentially leading to either duplication of medicines; 
alternatively, patients not taking their prescribed treatments as directed; consequently, not gaining the 
most benefit (58). These scenarios are exacerbated if pharmacists lack training on how to handle 
concerns with substitution and/ or do not receive payment for providing relevant information to patients 
potentially limiting the time spent with them (57, 59). INN prescribing, apart from a limited number of well-
known situations, is one way to address this as well as obtain low prices for generics when combined with 
increased knowledge on how the prices of generics are derived as well as any rebates and discounts in 
the system (23, 60). This has worked well in the UK with very high INN prescribing rates of 98 to 99% 
across a range of molecules (60). 
 
The authors accept that the there are several limitations to the study. These include the fact that there 
was no clinical information or diagnoses available in the database, and that only patients served by the 
private health care sector in South Africa were included in the study. We acknowledge that tenders  are 
used in the public sector in South Africa to enhance potential savings (35), and this currently includes 
10mg and 20mg simvastatin, However, there is limited access to utilisation and expenditure data in the 
public sector and this is not routinely collected electronically (61); patient dosing data is also not 
accurately recorded electronically. Consequently, we are unable to compare the findings between the two 
sectors. Overall, the authors believe the findings are still valid and provide guidance to all the authorities 
in South Africa in the future, especially given the broad provincial coverage of the medical insurance data 
used in the analysis. 
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Executive summary 
 
x Statins are recommended as first-line treatment in patients with hypercholesterolaemia and are used 
extensively to reduce morbidity and mortality, especially in high risk patients and for secondary 
prevention. However, there are concerns with their underdosing including South Africa 
x A study published in 2011 showed that there was underdoing of prescribed doses of simvastatin 
(23.7mg) but not for atorvastatin (20.91mg) or rosuvastatin (15.02mg). This needs to be addressed to 
help reduce coronary events in these patients, with potential activities including formularies, 
guidelines, prescribing targets and incentives mirroring the situation in the UK  
x There have been recent reforms in South Africa to increase the prescribing of generics in a class. 
This includes mandated generic substitution as well as additional co-payments if patients want a 
more expensive product than the available generic 
x These measures resulted in generic atorvastatin and simvastatin at 93% to 99% of total utilisation for 
these molecules (defined daily dose basis) in South Africa in 2011, with similar patterns seen in the 
Netherlands, Sweden and the UK. The utilisation of single sourced (patented) statins was only 22% of 
total statin utilisation (DDD basis) in South Africa in 2011, with low utilisation of ezetimibe (2.1% of 
total lipid lowering medicines) 
x This low utilisation of single sourced statins as well as ezetimibe mirrors patterns in the Netherlands, 
Sweden and the UK with their multiple demand-side measures 
x Prices of generic statins were 33% to 51% below originator prices in South Africa in 2011. This could 
be improved through a number of initiatives with prices of generic simvastatin at 96% to 98% below  
prices prior to the loss of patents in the Netherlands, Sweden and the UK through a variety of 
initiatives 
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